)
Andrew Dunn
Senior Biopharma Correspondent,
Endpoints News
United States
Andrew Dunn is a senior biopharma correspondent at Endpoints News, covering the money and science shaping the future of biotech and pharma. His beat focuses on AI in biotech, where he breaks news on startup launches, major financings, and the strategic moves defining the industry. He also reports deep enterprise stories from inside the labs and boardrooms of leading biopharma companies. A frequent moderator at industry conferences, Andrew launched Endpoints' AI Day in 2024.
Sessions
-
17-Jun-2025How VCs Evaluate Risk in Early Stage Startups
-
17-Jun-2025What are the Opportunities and Challenges for the New Generation of TechBio Partnerships Powered by Generative and Foundational AI?
-
19-Jun-2025Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
-
23-Jun-2026Breaking Down Silos: Building Multidisciplinary Teams for End-to-End AI Drug Development
-
24-Jun-2026Breaking Through the Noise: Building Marketable AI Platforms in Biotech
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}